1 / 81

Antineoplastics and Antianemics

Antineoplastics and Antianemics. Pharmacology NURS 1950. Objective 1: Describe the general factors utilized to select the therapy used to treat cancer Surgery Radiation Chemotherapy Most effective against rapidly growing cells.

tasya
Télécharger la présentation

Antineoplastics and Antianemics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antineoplastics and Antianemics Pharmacology NURS 1950

  2. Objective 1: Describe the general factors utilized to select the therapy used to treat cancer • Surgery • Radiation • Chemotherapy • Most effective against rapidly growing cells

  3. Objective 2: Describe the general uses of chemotherapy in the treatment of cancer • Through blood • Into body cavities • As adjuvant therapy

  4. Therapy terms • Cure: • Palliation • prophylaxis

  5. Objective 3: Identify the basic types of antineoplastic drugs

  6. Cell cycle • G0 Phase: resting stage • G1 Phase: synthesizes material needed to duplicate DNA • S Phase: duplicates DNA • G2 Phase: premitotic phase • M Phase: mitosis occurs • Cell returns to G0 phase

  7. Alkylating agents • Antimetabolites • Natural products • Antineoplastic antibiotics • Hormones • Biologic response modifiers & Misc.

  8. Alkylating Agents • Bond with DNA so it can’t separate = no replication • Cell-cycle nonspecific • Resistance can be a problem • Creates cross resistance with other alkylating agents

  9. Alkylating agents: non cell cycle specific drugs • Activity occurs when the cell tries to replicate and the DNA can not separate • Blood cells are very sensitive/responsive to this activity

  10. Drugs included • Busulfan (Myleran) • Carboplatin (Paraplatin) • Carmustine (BCNU) • Chloramubil (Leukeran) • Cisplatin (Platinol) • Cyclophosphamide (Cytoxan) • prototype

  11. Fudarabine (Fludara) • Lomustine (CCNU, CeeNU) • Mechlorethamine (Nitrogen mustard, Mustargen) • Melphalan (Alkeran) • Streptozocin (Zanosar) • Thiotepa

  12. In general, toxicities include • N/V, anorexia • Bone marrow depression • Anemia • Nephrotoxicity • Hepatic and renal toxicity • Alopecia • Cystitis • infertility

  13. Nursing Interventions • Discontinue if RBC, WBC and platelet counts fall • Caution use: hepatic or renal impairment • Hydrate before chemo—IV or oral • Advise to avoid crowds • Monitor nutritional intake • Assess for N/V—admin meds as needed • Offer non meds to relieve mouth pain

  14. Interventions con’t • Assess skin integrity • Monitor for hearing loss • Inform regarding impact of infertility • Maintain strict medical asepsis

  15. Each drug may have specific toxicities • Example: Zanosar causes hypoglycemia

  16. Antimetabolites • Drugs included • Capecitabine (Xeloda) • Cytarabine hydrochloride (Cytosar) • Fludarabine (Fludara) • Flurouracil (5-FU, FU) • Gemcitabine (Gemzar)

  17. Mercaptopurine (6-MP, Purinethol) • Methotrexate (MTX) prototype • Overdosed: Leucovorin as rescue drug • Thioguanine (Lanvis)

  18. Antimetabolites are subclassed as folic acid, purine, and pyrimidine antagonists • Inhibit key enzymes in biosynthetic pathways of DNA and RNA synthesis • Many are cell-cycle specific (S phase) • Uses: choriocarcinoma, breast, head and neck and lung ca, leukemia

  19. In general, toxicities include • N/V, diarrhea, constipation, fatigue • Bone marrow depression, dermatitis • Oral and GI ulceration

  20. Nursing interventions • Contraindicated in pregnancy, hepatic and renal insufficiency, cardiac conditions • Avoid pregnancy for 6 months with category X drug • Monitor for photosensitivity and idiosyncratic pneumonitis • Teach good oral hygiene, mouth rinses • Monitor IV site for extravasation

  21. Natural Products/mitotic inhibitors • Come from periwinkle plant, specific yews • Cell-cycle specific: block mitotic spindle during mitosis • Use: Hodgkins, non hodgkins, Karposi, Wilm’s tumor, bladder and breast CA

  22. Drugs include • Etoposide (VePesid) • Docetaxel (Taxotere) • Paclitaxel • Vinblastine sulfate (Velban, Velbe) • Vincristine sulfate (Oncovin) Prototype • Vinorelbine (Navelbine)

  23. Nursing interventions • Assess for allergies to plants, foods • Vincristine may produce acute broncho spasm and rash • Ask about pregnancy/breast feeding • Emphasize nutritional plan to combat constipation • Monitor BP; watch for syncope, HA, dizziness • May produce mental depression; assess for suicidal ideation

  24. General toxicities • N/V, stomatitis • Leukopenia with VePesid: nadir in 10-14 days, recovery 3 weeks • Bone marrow suppression, alopecia, peripheral neuritis, hepatotoxicity, bronchospasm

  25. Antineoplastic Antibiotics • Bind to DNA, inhibit DNA, RNA synthesis • Cell-cycle nonspecific • Admin IV or via catheter to body cavity • Use: breast, bladder, lung, ovary

  26. Drugs include • Bleomycin (Blenoxane) • Dactinomycin (Actinomycin D, Cosmegen) • Daunorubicin (Cerubidine) • Doxorubicin (Adriamycin) • prototype • Epirubicin (Ellence)

  27. Idarubicin • Mitomycin C • Mitoxantrone • Plicamycin • Valrubicin • Bladder specific

  28. Generally, toxicities include • N/V, red tinged urine with some • Bone marrow depression • Cardiotoxicity • Pulmonary fibrosis (Bleomycin) • GI bleeding, CNS effects with some

  29. Nursing interventions • Assess cardiac status—EKG • Ask about pregnancy/lactation • Risk of hypersensitivity as in other antibx • No rectal suppositories or temp due to rectal mucosal changes • Wear protective clothing when preparing drug • Monitor IV site • Give drug thru large bore, quickly running IV

  30. Hormones • Corticosteroids: lymphoma and acute leukemia as suppress mitosis in lymphocytes • Help restore sense of well being, decrease edema with radiation, increase appetite and strength • Action: mostly unknown

  31. Estrogens and androgens: malignancies of sexual organs • Use estrogen for prostate cancer (suppress the amount of androgen available) • Use androgens for breast cancer (suppress the amount of estrogen available) • Normally given as palliation

  32. Drugs included • Anastrozole (Arimidex) • Diethylstilbestrol (DES) • Prednisone • Tamoxifen (Nolvadex) • prototype • Testolactone (Teslac) • Testosterone

  33. General toxicities • N/V, headache • Fluid retention, feminization or masculinization • Hot flashes • Some can cause thrombocytopenia, leukopenia, hypercalcemia, increased bone and tumor pain

  34. Nursing interventions • Assess for pregnancy/lactation • Tamoxifen is only ‘curative’ drug • Important that family knows and understands limitations of this category • Fertility affected

  35. Biologic response modifiers • Drugs included • Altretamine (Hexalen) • Dacarbazine (DTIC-dome) • Hydroxyurea (Hydrea) • Interferon alfa-2b (Intran) • prototype • Leuprolide acetate (Lupron) Action: stimulate immune system to fight tumor cell growth

  36. Toxicities in general • N/V, hot flashes, bone marrow depression, arrhythmias • Flulike syndrome • Anemia, leukopenia • Less toxic than other CA drugs

  37. Immunomodulators • Drugs used as adjunct therapy • Epoetin alfa (Procrit) stimulates production of red blood cells • Used to treat anemia induced by chemotherapy • Increased risk of thrombus formation

  38. Colony Stimulating Factors • Filgastim (Neupogen) stimulates the production of neutrophils (WBC)

  39. Monoclonal antibodies • Rituximab (Rituxan) binds to the surface of B lymphocytes • Used to treat relapsed B-cell non-Hodgkin’s lymphoma

  40. Colony stimulating factor • Sargramostim (Leukine) stimulates the production of granulocytes and macrophages • Also helpful in aplastic anemia • Side effects: • Resp distress with initial dosing • Follow protocol • Use: AML, bone marrow transplant

  41. Platelet enhancer • Oprelvekin (Neumega) stimulates platelet production at stem cell level

  42. Monoclonal antibody • Trastuzumab (Herceptin) inhibits growth of tumor cells (especially useful in metastatic breast cancer) • Binds to specific protein in breast ca cells that leads to death of cell.

  43. New class: antiangiogenesis • Prevent new blood vessels

  44. Multiple Drug Strategy • Multiple drugs from different classes • Affect different stages in cell cycle • Use different mechanisms of action to increase cell kill • Combinations allow for lower doses • Reduce toxicity • Slow development of resistance

  45. Dosing schedules • Specific dosing protocols • Depend on the type of tumor, stage of disease, overall condition of the client • Given as single dose or several • Over days or weeks • Allows normal cells to recover • Sometimes doses needs to be delayed • Allow client to recover • ie bone marrow depression

  46. Objective 4: identify the 2 factors that play a major role in the response of the cancer cell to the antineoplastic drug • Tumor size • Rate of cell replication

  47. Objective 5: describe what “tumor resistance” means • Tumor cells are not as susceptible to antineoplastic agents as they should be • Cells escape damage from the drugs

  48. Objective 6: specify which normal cells are frequently affected by antineoplastic therapy; and signs and symptoms that result most frequently

More Related